Adrian Rawcliffe, Adaptimmune

from Being a Life Sciences Leader · host Life Sciences Pennsylvania

Send us Fan MailThis episode features Adrian (Ad) Rawcliffe, CEO, Adaptimmune, recipient of the Life Sciences PA 2024 Patient Impact Award.Ad shares the story behind TECELRA - the first FDA approved engineered cell therapy for a solid tumor. Learn about the journey leading up to this groundbreaking approval, the challenges of bringing a cell therapy to market and the next steps for Adaptimmune in the landscape of tumor treatments.

Episode metadata supplied by the publisher feed · Published Mar 5, 2025

Embed this episode

Attribution link and audio player

Ready to play

Adrian Rawcliffe, Adaptimmune

0:00 29:14

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Being a Life Sciences Leader?

This episode is 29 minutes long.

When was this Being a Life Sciences Leader episode published?

This episode was published on March 5, 2025.

Can I download this Being a Life Sciences Leader episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!